Alignment Healthcare Inc. (ALHC) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, ALHC scores 56 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

• Fundamental Cash Engine: 17 / 20. Per the RQD rating, this pillar reflects ROIC of 13.9% and an FCF yield of 6.77%. This is the strongest pillar and is the main upside argument in the scoring: the company's reported cash generation and capital return metrics are comparatively solid relative to its other pillars.
• Whale 13F Flow: 5 / 20. Per the RQD rating, this covers institutional accumulation and options positioning. The low score indicates limited supporting institutional flow in the rating's framework; the holders section of the source data is empty, so the underlying flow cannot be examined further here.
• Insider Conviction: 15 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The score is moderate; the specific trades are not itemized in the source data.
• Macro Regime Fit: 7 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. The low score suggests the rating views the stock's exposure to market and sector conditions as a weakness rather than a cushion.
• Forensic Balance Sheet: 12 / 20. Per the RQD rating, Altman Z is 4, Piotroski F is 6/9, and Debt/Equity is 1.8. This is a middling reading: the Piotroski score is reasonable, but the leverage ratio is elevated.

Taken together, the rating frames ALHC as a stock whose cash-generation metrics are its best feature, offset by weak institutional flow, macro exposure, and leverage. For a prospective investor, the upside case rests on the cash engine persisting; the valuation tradeoff is that the enterprise value multiple is high relative to the reported operating margin of 0.4%. The rating's verdict is a negative assessment, and a prospective investor would weigh it against the company's own disclosed trajectory rather than treat it as a timing signal.

Alignment Healthcare Inc. (ALHC) is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry, per the company profile. The source data does not describe its products, customers, or revenue model beyond this classification. Its reported FY 2025 revenue of $3948.7M indicates a substantial operating scale, but the source data does not state the segments or payer mix that generate it.

Revenue grew from $1800.9M in FY 2023 to $3948.7M in FY 2025, and operating income moved from negative to positive $14.8M in FY 2025. Net income was still slightly negative at $-0.7M in FY 2025. Per the market data, the operating margin is 0.4%, the gross and net margins are 0%, and ROIC is 13.9%. Per the RQD rating, the Altman Z-Score is 4 and the Piotroski F-Score is 6/9; the Debt/Equity ratio is 1.8. Cash of $575.8M exceeded debt of $323.2M at FY 2025 year-end.

The news feed contains six headlines from Yahoo Finance, Benzinga, and Investing.com, all tagged to ALHC and flagged with a YELLOW light and "MARKET WIRE" impact label. Their titles point to the stock having recently both fallen ("Why Is Alignment Healthcare Stock Tumbling Today?") and risen ("Why Alignment Healthcare (ALHC) Stock Is Up Today"), and one describes the stock as fairly valued "Despite Earnings Questions." The summaries are generic and do not state the underlying catalyst, so the specific drivers of these moves are not available in source data. The feed contains no quantified earnings, guidance, or regulatory events. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

• What specific events drove the recent price declines and rebounds described in the news headlines?
• What are the company's EPS and P/E figures, which are absent from the source data and needed to judge the 37.8 EV/EBITDA multiple?
• What is the composition of the $3948.7M FY 2025 revenue, including segments and payer mix?
• What debt maturities and terms underlie the $323.2M debt balance and the 1.8 Debt/Equity ratio?
• Who holds the shares, and what institutional or insider activity supports or contradicts the low 13F flow score?